Genetic rickets improves more with burosumab than standard care, study finds

(The Endocrine Society) Burosumab, a new injectable medicine to treat X-linked hypophosphatemia (XLH), an inherited form of rickets, demonstrates superior improvements in rickets and other outcomes compared with conventional therapy in an international, phase 3 clinical trial in children. Results from what investigators called the first head-to-head study comparing the new drug with conventional treatment for this rare disease will be presented Sunday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news